{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:48:48Z","timestamp":1761238128205},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,9,12]],"date-time":"2014-09-12T00:00:00Z","timestamp":1410480000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/s12888-014-0253-4","type":"journal-article","created":{"date-parts":[[2014,9,11]],"date-time":"2014-09-11T10:37:32Z","timestamp":1410431852000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Treatment resistant schizophrenia: a comprehensive survey of randomised controlled trials"],"prefix":"10.1186","volume":"14","author":[{"given":"Diarmid","family":"Sinclair","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clive E","family":"Adams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,9,12]]},"reference":[{"issue":"4","key":"253_CR1","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1017\/S0033291700045244","volume":"2","author":"N Sartorius","year":"1972","unstructured":"Sartorius N, Shapiro R, Kimura M, Barrett K: WHO international pilot study of schizophrenia. Psychol Med. 1972, 2 (4): 422-425. 10.1017\/S0033291700045244.","journal-title":"Psychol Med"},{"key":"253_CR2","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1192\/bjp.178.6.506","volume":"178","author":"G Harrison","year":"2001","unstructured":"Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J, Dube KC, Ganev K, Giel R, an der Heiden W: Recovery from psychotic illness: a 15- and 25-year international follow-up study. Br J Psychiatry. 2001, 178: 506-517. 10.1192\/bjp.178.6.506.","journal-title":"Br J Psychiatry"},{"issue":"1","key":"253_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1185\/03007999709113338","volume":"14","author":"HY Meltzer","year":"1997","unstructured":"Meltzer HY: Treatment-resistant schizophrenia-the role of clozapine. Curr Med Res Opin. 1997, 14 (1): 1-20. 10.1185\/03007999709113338.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"253_CR4","first-page":"23","volume":"10","author":"R Mangalore","year":"2007","unstructured":"Mangalore R, Knapp M: Cost of schizophrenia in England. J Ment Health Policy Econ. 2007, 10 (1): 23-41.","journal-title":"J Ment Health Policy Econ"},{"issue":"1-3","key":"253_CR5","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.schres.2011.09.016","volume":"133","author":"T Suzuki","year":"2011","unstructured":"Suzuki T, Remington G, Mulsant BH, Rajji TK, Uchida H, Graff-Guerrero A, Mamo DC: Treatment resistant schizophrenia and response to antipsychotics: a review. Schizophr Res. 2011, 133 (1-3): 54-62. 10.1016\/j.schres.2011.09.016.","journal-title":"Schizophr Res"},{"issue":"9","key":"253_CR6","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","volume":"45","author":"J Kane","year":"1988","unstructured":"Kane J, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988, 45 (9): 789-796. 10.1001\/archpsyc.1988.01800330013001.","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"253_CR7","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1093\/schbul\/23.4.663","volume":"23","author":"RR Conley","year":"1997","unstructured":"Conley RR, Buchanan RW: Evaluation of treatment-resistant schizophrenia. Schizophr Bull. 1997, 23 (4): 663-674. 10.1093\/schbul\/23.4.663.","journal-title":"Schizophr Bull"},{"key":"253_CR8","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1176\/ajp.2006.163.4.600","volume":"163","author":"JP McEvoy","year":"2006","unstructured":"McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK: Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006, 163: 600-610. 10.1176\/appi.ajp.163.4.600.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"253_CR9","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1093\/schbul\/sbj067","volume":"32","author":"SW Lewis","year":"2006","unstructured":"Lewis SW, Barnes TR, Davies L, Murray RM, Dunn G, Hayhurst KP, Markwick A, Lloyd H, Jones PB: Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull. 2006, 32 (4): 715-723. 10.1093\/schbul\/sbj067.","journal-title":"Schizophr Bull"},{"issue":"1","key":"253_CR10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.schres.2012.03.018","volume":"138","author":"JA Gallego","year":"2012","unstructured":"Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU: Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res. 2012, 138 (1): 18-28. 10.1016\/j.schres.2012.03.018.","journal-title":"Schizophr Res"},{"issue":"6","key":"253_CR11","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1192\/bjp.bp.111.105833","volume":"201","author":"OD Howes","year":"2012","unstructured":"Howes OD, Vergunst F, Gee S, McGuire P, Kapur S, Taylor D: Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry. 2012, 201 (6): 481-485. 10.1192\/bjp.bp.111.105833.","journal-title":"Br J Psychiatry"},{"issue":"3","key":"253_CR12","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/schbul\/18.3.515","volume":"18","author":"HY Meltzer","year":"1992","unstructured":"Meltzer HY: Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophr Bull. 1992, 18 (3): 515-542. 10.1093\/schbul\/18.3.515.","journal-title":"Schizophr Bull"},{"issue":"11","key":"253_CR13","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.jclinepi.2004.02.018","volume":"57","author":"TA Trikalinos","year":"2004","unstructured":"Trikalinos TA, Churchill R, Ferri M, Leucht S, Tuunainen A, Wahlbeck K, Ioannidis JP: Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time. J Clin Epidemiol. 2004, 57 (11): 1124-1130. 10.1016\/j.jclinepi.2004.02.018.","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"253_CR14","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, Devereaux PJ, Montori VM, Freyschuss B, Vist G, Jaeschke R, Williams JW, Murad MH, Sinclair D, Falck-Ytter Y, Meerpohl J, Whittington C, Thorlund K, Andrews J, Sch\u00fcnemann HJ: GRADE guidelines 6. Rating the quality of evidence-imprecision. J Clin Epidemiol. 2011, 64 (12): 1283-1293. 10.1016\/j.jclinepi.2011.01.012.","journal-title":"J Clin Epidemiol"},{"key":"253_CR15","volume-title":"About the Cochrane collaboration (Cochrane Review Groups (CRGs)","author":"CE Adams","year":"2013","unstructured":"Adams CE, Davis J, Duggan L, Essali A, Fenton M, Leucht S, Jayaram M, Li C, Tharyan P, V\u00e4lim\u00e4ki M, Cochrane Schizophrenia Group: About the Cochrane collaboration (Cochrane Review Groups (CRGs). Issue 8. Art. No.: SCHI."},{"key":"253_CR16","first-page":"CD008712","volume":"4","author":"C Jones","year":"2012","unstructured":"Jones C, Hacker D, Cormac I, Meaden A, Irving CB: Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia. Cochrane Database Syst Rev. 2012, 4: CD008712-","journal-title":"Cochrane Database Syst Rev"},{"key":"253_CR17","doi-asserted-by":"crossref","unstructured":"Pharoah F, Mari Jair J, Rathbone J, Wong W: Family intervention for schizophrenia. Cochrane Database Syst Rev 2010, (12):Art. No.: CD000088. doi:10.1002\/14651858.CD000088.pub3","DOI":"10.1002\/14651858.CD000088.pub3"},{"key":"253_CR18","doi-asserted-by":"crossref","unstructured":"Rathbone J, Xia J: Acupuncture for schizophrenia. Cochrane Database Syst Rev 2005, (4):Art. No.: CD005475. doi:10.1002\/14651858.CD005475","DOI":"10.1002\/14651858.CD005475"},{"key":"253_CR19","doi-asserted-by":"crossref","unstructured":"Tharyan P, Adams Clive E: Electroconvulsive therapy for schizophrenia. Cochrane Database Syst Rev 2005, (2):Art. No.: CD000076. doi:10.1002\/14651858.CD000076.pub2","DOI":"10.1002\/14651858.CD000076.pub2"},{"key":"253_CR20","doi-asserted-by":"crossref","unstructured":"Dougall N, McIntosh A, Ebmeier Klaus P: Transcranial magnetic stimulation for schizophrenia. Cochrane Database Syst Rev 2006, (3):Art. No.: CD006081. doi:10.1002\/14651858.CD006081.","DOI":"10.1002\/14651858.CD006081"},{"key":"253_CR21","doi-asserted-by":"crossref","unstructured":"Cipriani A, Boso M, Barbui C: Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst Rev 2009, (3):Art. No.: CD006324. doi:10.1002\/14651858.CD006324.pub2.","DOI":"10.1002\/14651858.CD006324.pub2"},{"key":"253_CR22","doi-asserted-by":"crossref","unstructured":"Wang J, Omori Ichiro M, Fenton M, Soares Bernardo GO: Sulpiride augmentation for schizophrenia. Cochrane Database Syst Rev. 2010, (1): Art. No.: CD008125-doi:10.1002\/14651858.CD008125.pub2","DOI":"10.1002\/14651858.CD008125.pub2"},{"key":"253_CR23","doi-asserted-by":"crossref","unstructured":"Schwarz C, Volz A, Li C, Leucht S: Valproate for schizophrenia. Cochrane Database Syst Rev. 2008, (3): Art. No.: CD004028-doi:10.1002\/14651858.CD004028.pub3","DOI":"10.1002\/14651858.CD004028.pub3"},{"key":"253_CR24","doi-asserted-by":"crossref","unstructured":"Premkumar TS, Pick J: Lamotrigine for schizophrenia. Cochrane Database Syst Rev. 2006, (4): CD005962-doi:10.1002\/14651858.CD005962.pub2","DOI":"10.1002\/14651858.CD005962.pub2"},{"key":"253_CR25","doi-asserted-by":"crossref","unstructured":"Leucht S, Kissling W, McGrath J: Lithium for schizophrenia. Cochrane Database Syst Rev. 2007, (3): CD003834-doi:10.1002\/14651858.CD003834.pub2","DOI":"10.1002\/14651858.CD003834.pub2"},{"key":"253_CR26","doi-asserted-by":"crossref","unstructured":"Kour K, Kaur R, Singh J: Memantine for schizophrenia. Cochrane Database Syst Rev. 2013, (6): Art. No.: CD010552-doi:10.1002\/14651858.CD010552","DOI":"10.1002\/14651858.CD010552"},{"key":"253_CR27","doi-asserted-by":"crossref","unstructured":"Tiihonen J, Wahlbeck K: Glutamatergic drugs for schizophrenia. Cochrane Database Syst Rev. 2006, (2): Art. No.: CD003730-doi:10.1002\/14651858.CD003730.pub2","DOI":"10.1002\/14651858.CD003730.pub2"},{"key":"253_CR28","doi-asserted-by":"crossref","unstructured":"Leucht S, Helfer B, Dold M, Kissling W, McGrath J: Carbamazepine for schizophrenia. Cochrane Database Syst Rev. 2014, (5): Art. No.: CD001258-doi:10.1002\/14651858.CD001258.pub3","DOI":"10.1002\/14651858.CD001258.pub3"},{"key":"253_CR29","unstructured":"Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Silveira da Mota Neto Joaquim I, Kissling W, Leucht S: Amisulpride versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010, (1): Art. No.: CD006624-doi:10.1002\/14651858.CD00624.pub2"},{"key":"253_CR30","doi-asserted-by":"crossref","unstructured":"Khanna P, Suo T, Komossa K, Ma H, Rummel-Kluge C, El-Sayeh Hany G, Leucht S, Xia J: Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2014, (1): Art. No.: CD006569-doi:10.1002\/14651858.CD006569.pub5","DOI":"10.1002\/14651858.CD006569.pub5"},{"key":"253_CR31","doi-asserted-by":"crossref","unstructured":"Essali A, Al-Haj Haasan N, Li C, Rathbone J: Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev. 2009, (1): Art. No.: CD000059-doi:10.1002\/14651858.CD000059.pub2","DOI":"10.1002\/14651858.CD000059.pub2"},{"key":"253_CR32","doi-asserted-by":"crossref","unstructured":"Asenjo Lobos C, Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Leucht S: Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010, (11): Art. No.: CD006633-doi:10.1002\/14651858.CD006633.pub2","DOI":"10.1002\/14651858.CD006633.pub2"},{"key":"253_CR33","doi-asserted-by":"crossref","unstructured":"Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Duggan L, Kissling W, Leucht S: Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010, (3): Art. No.: CD006654-doi:10.1002\/14651858.CD006654.pub2,","DOI":"10.1002\/14651858.CD006654.pub2"},{"key":"253_CR34","doi-asserted-by":"crossref","unstructured":"Li C, Xia J, Wang J: Risperidone dose for schizophrenia. Cochrane Database Syst Rev. 2009, (4): Art. No.: CD007474-doi:10.1002\/14651858.CD007474.pub2","DOI":"10.1002\/14651858.CD007474.pub2"},{"key":"253_CR35","doi-asserted-by":"crossref","unstructured":"Komossa K, Rummel-Kluge C, Schwarz S, Schmid F, Hunger H, Kissling W, Leucht S: Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2011, (1): Art. No.: CD006626-doi:10.1002\/14651858.CD006626.pub2","DOI":"10.1002\/14651858.CD006626.pub2"},{"key":"253_CR36","doi-asserted-by":"crossref","unstructured":"Hunter R, Kennedy E, Song F, Gadon L, Irving Claire B: Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev. 2003, (2): Art. No.: CD000440-doi:10.1002\/14651858.CD000440.","DOI":"10.1002\/14651858.CD000440"},{"key":"253_CR37","doi-asserted-by":"crossref","unstructured":"Asmal L, Flegar Srnka J, Wang J, Rummel-Kluge C, Komossa K, Leucht S: Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2013, (11): Art. No.: CD006625-doi:10.1002\/14651858.CD006625.pub3","DOI":"10.1002\/14651858.CD006625.pub3"},{"key":"253_CR38","doi-asserted-by":"crossref","unstructured":"Komossa K, Rummel-Kluge C, Hunger H, Schwarz S, Schmid F, Lewis R, Kissling W, Leucht S: Sertindole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2009, (42): Art. No.: CD006752-doi:10.1002\/14651858.CD006752.pub2","DOI":"10.1002\/14651858.CD006752.pub2"},{"key":"253_CR39","doi-asserted-by":"crossref","unstructured":"Komossa K, Rummel-Kluge C, Hunger H, Schwarz S, Bhoopathi Paranthaman S, Kissling W, Leucht S: Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2009, (4): Art. No.: CD006627-doi:10.1002\/14651858.CD006627.pub2","DOI":"10.1002\/14651858.CD006627.pub2"},{"key":"253_CR40","doi-asserted-by":"crossref","unstructured":"Saha Kumar B, Sampson S, Zaman Rashid U: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2013, (2): Art. No.: CD010631-doi:10.1002\/14651858.CD010631","DOI":"10.1002\/14651858.CD010631"},{"key":"253_CR41","doi-asserted-by":"crossref","unstructured":"Sampford J, Sampson S: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2013, (11): Art. No.: CD010832-doi:10.1002\/14651858.CD010832","DOI":"10.1002\/14651858.CD010832"},{"key":"253_CR42","doi-asserted-by":"crossref","unstructured":"Tardy M, Leucht S, Potapov A, Engel R, Huhn M, Kissling W: Fluphenazine versus low-potency first generation antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2011, (8): Art. No.: CD009230-doi:10.1002\/14651858.CD009230.pub2","DOI":"10.1002\/14651858.CD009230.pub2"},{"key":"253_CR43","doi-asserted-by":"crossref","unstructured":"Dold M, Li C, Tardy M, Leucht S: Haloperidol versus first generation antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2012, (5): Art. No.: CD009831-doi:10.1002\/14651858.CD009831","DOI":"10.1002\/14651858.CD009831"},{"key":"253_CR44","doi-asserted-by":"crossref","unstructured":"Tardy M, Leucht S, Potapov A, Engel R, Huhn M, Kissling W: Perphenazine versus low-potency first generation antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2011, (10): Art. No.: CD009369-doi:10.1002\/14651858.CD009369","DOI":"10.1002\/14651858.CD009369"},{"issue":"7351","key":"253_CR45","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/474277a","volume":"474","author":"K Lloyd","year":"2011","unstructured":"Lloyd K, White J: Democratizing clinical research. Nature. 2011, 474 (7351): 277-278. 10.1038\/474277a.","journal-title":"Nature"},{"issue":"1","key":"253_CR46","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1600-0447.2011.01792.x","volume":"125","author":"DM Taylor","year":"2012","unstructured":"Taylor DM, Smith L, Gee SH, Nielsen J: Augmentation of clozapine with a second antipsychotic - a meta-analysis. Acta Psychiatr Scand. 2012, 125 (1): 15-24. 10.1111\/j.1600-0447.2011.01792.x.","journal-title":"Acta Psychiatr Scand"},{"key":"253_CR47","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1471-244X-5-26","volume":"5","author":"DA-SH Faries","year":"2005","unstructured":"Faries DA-SH, Zhu B, Correll C, Kane J: Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry. 2005, 5: 26-10.1186\/1471-244X-5-26.","journal-title":"BMC Psychiatry"},{"issue":"3","key":"253_CR48","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.rpsm.2013.01.001","volume":"6","author":"SM Stahl","year":"2013","unstructured":"Stahl SM: Emerging guidelines for the use of antipsychotic polypharmacy. Revista de psiquiatria y salud mental. 2013, 6 (3): 97-100.","journal-title":"Revista de psiquiatria y salud mental"},{"key":"253_CR49","unstructured":"NICE: Psychosis and schizophrenia in adults: treatment and management. In NICE clinical guideline 178. Available at[ www.nice.org.uk\/CG178 [NICE guideline]."},{"issue":"2","key":"253_CR50","first-page":"1","volume":"161","author":"AF Lehman","year":"2004","unstructured":"Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J: Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004, 161 (2): 1-56.","journal-title":"Am J Psychiatry"},{"issue":"11","key":"253_CR51","doi-asserted-by":"publisher","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","volume":"135","author":"LL Kjaergard","year":"2001","unstructured":"Kjaergard LL, Villumsen J, Gluud C: Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med. 2001, 135 (11): 982-989. 10.7326\/0003-4819-135-11-200112040-00010.","journal-title":"Ann Intern Med"},{"issue":"2","key":"253_CR52","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1001\/jama.1994.03520020048013","volume":"272","author":"D Moher","year":"1994","unstructured":"Moher D, Dulberg CS, Wells GA: Statistical power, sample size, and their reporting in randomized controlled trials. JAMA. 1994, 272 (2): 122-124. 10.1001\/jama.1994.03520020048013.","journal-title":"JAMA"},{"key":"253_CR53","first-page":"790","volume":"10","author":"JE Overall","year":"1962","unstructured":"Overall JE, Gorham DR: The brief psychiatric rating scale. Psychol Rep. 1962, 10: 790-812.","journal-title":"Psychol Rep"},{"issue":"4","key":"253_CR54","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1192\/bjp.187.4.366","volume":"187","author":"S Leucht","year":"2005","unstructured":"Leucht S, Kane JM, Kissling W, Hamann J, Etschel EVA, Engel R: Clinical implications of brief psychiatric rating scale scores. Br J Psychiatry. 2005, 187 (4): 366-371. 10.1192\/bjp.187.4.366.","journal-title":"Br J Psychiatry"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12888-014-0253-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-014-0253-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-014-0253-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T12:38:01Z","timestamp":1551184681000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-014-0253-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,12]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["253"],"URL":"https:\/\/doi.org\/10.1186\/s12888-014-0253-4","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,12]]},"article-number":"253"}}